A Phase 4 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 27 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-08-03.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 11th largest by enrollment, is one of 12 that started in 2012, is one of 5 in phase 4, and was the 21st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 19 finished, 9 (47%) have results posted.
Among the 19 studies in Hepatitis C by Vertex Pharmaceuticals Incorporated, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2012, is the only one in phase 4, and was the 15th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 19 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC), who have not achieved a sustained viral response with a prior course of interferon-based therapy.
This is a single-arm, open-label, multicenter study of treatment-experienced participants with Genotype 1 CHC, who self-identified as Black/African American (Group A) or who did not self-identify as Black/African American (Group B). Participants did not achieve a sustained virologic response 24 weeks after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of standard duration, and have 1 of the following viral responses:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing \<75 kilograms \[kg\]) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.
Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a
Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing \<75 kg) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.
Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a
Tablet
Also known as: Incivek, VX-950
Tablet
Also known as: Copegus®, RBV
Subcutaneous Injection
Also known as: Pegasys®, Peg-IFN-Alfa-2a
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
Time frame: 12 weeks after last actual dose of study drug (up to Week 60)
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)
SVR24 was defined as an undetectable HCV RNA Levels (\<lower limit of quantification) at 24 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.
Time frame: 24 weeks after last actual dose of study drug (up to Week 72)
Percentage of Participants With Extended Rapid Viral Response (eRVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
Time frame: Week 4 and Week 12
Percentage of Participants With Relapse
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Relapse was defined as having undetectable HCV RNA (\<lower limit of quantification) at actual end of treatment (EOT) and followed by detectable HCV RNA (\>=lower limit of quantification) during follow-up.
Time frame: 4 weeks (Wk) (up to Week 52), 12 weeks (up to Week 60) and 24 weeks (up to Week 72) after actual EOT
Percentage of Participants With Virologic Breakthrough
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Virologic breakthrough on treatment was defined as an increase of at least 1 log10 from nadir or confirmed detectable HCV RNA (\>=lower limit of quantification) after undetectable HCV RNA (\<lower limit of quantification). Percentages are calculated by using total number in FA set as denominator, in each category.
Time frame: Week 2, 4, 8, and 12
Percentage of Participants With On Treatment Virologic Failure
On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Futility rules: 1) Virologic breakthrough (at least 1 log10 increase from nadir or confirmed detectable HCV RNA after undetectable HCV RNA) from Day 1 through Week 24 or 48 (depending on treatment duration); 2) HCV RNA \>1000 IU/mL during Weeks 4 to 12, inclusive; 3) Detectable HCV RNA after Week 12. Percentages are calculated by using total number in FA set as denominator, in each category.
Time frame: Week 2, 4, 8, 12, 16, 24, 28, 36, 40, and 48
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes SAE as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
Time frame: Up to Week 52
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by race and by prior response.
Time frame: up to Week 72
Plasma Concentration of Telaprevir, Peginterferon Alfa-2a (Peg-IFN) and Ribavirin (RBV)
Time frame: 48 weeks
Study included Prior Relapser (prior HCV treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse) and Prior Null/Partial Responder (prior HCV treatment with Peg-IFN/RBV and had null/partial response) participants.
| Milestone | Group A - Black | Group B - Non-Black |
|---|---|---|
| Started | 83 | 38 |
| Completed | 61 | 25 |
| Not completed | 22 | 13 |
| Withdrew: Withdrawal by subject | 6 | 4 |
| Withdrew: Study terminated by sponsor | 6 | 4 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Undefined | 2 | 0 |
| Withdrew: Enrolled but not treated | 1 | 0 |
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response (n = 41, 10) | 26.8 | 20.0 |
| Prior Partial Response (n= 20, 6) | 40.0 | 33.3 |
| Prior Relapse ( n= 21, 22) | 66.7 | 59.1 |
| Total (n= 82, 38) | 40.2 | 44.7 |
SVR24 was defined as an undetectable HCV RNA Levels (\<lower limit of quantification) at 24 weeks after last actual dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response (n = 41, 10) | 19.5 | 20.0 |
| Prior Partial Response (n= 20, 6) | 30.0 | 16.7 |
| Prior Relapse ( n= 21, 22) | 61.9 | 50.0 |
| Total (n= 82, 38) | 32.9 | 36.8 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response (n = 41, 10) | 24.4 | 30.0 |
| Prior Partial Response (n= 20, 6) | 45.0 | 66.7 |
| Prior Relapse ( n= 21, 22) | 66.7 | 68.2 |
| Total (n= 82, 38) | 40.2 | 57.9 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Relapse was defined as having undetectable HCV RNA (\<lower limit of quantification) at actual end of treatment (EOT) and followed by detectable HCV RNA (\>=lower limit of quantification) during follow-up.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response, 4 Wk After EOT (n=17,3) | 23.5 | 33.3 |
| Prior Null Response, 12 Wk After EOT (n=17,3) | 23.5 | 33.3 |
| Prior Null Response, 24 Wk After EOT (n=17,3) | 29.4 | 33.3 |
| Prior Partial Response, 4Wk After EOT (n=13,4) | 15.4 | 50.0 |
| Prior Partial Response, 12 Wk After EOT (n=13,4) | 23.1 | 50.0 |
| Prior Partial Response, 24 Wk After EOT (n=13,4) | 23.1 | 50.0 |
| Prior Relapse, 4 Wk After EOT (n=18,19) | 11.1 | 15.8 |
| Prior Relapse, 12 Wk After EOT (n=18,19) | 11.1 | 26.3 |
| Prior Relapse, 24 Wk After EOT (n=18,19) | 11.1 | 26.3 |
| Total, 4 Wk After EOT (n=48,26) | 16.7 | 23.1 |
| Total, 12 Wk After EOT (n=48,26) | 18.8 | 30.8 |
| Total, 24 Wk After EOT (n=48,26) | 20.8 | 30.8 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Virologic breakthrough on treatment was defined as an increase of at least 1 log10 from nadir or confirmed detectable HCV RNA (\>=lower limit of quantification) after undetectable HCV RNA (\<lower limit of quantification). Percentages are calculated by using total number in FA set as denominator, in each category.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response, Week 2 | 0 | 0 |
| Prior Null Response, Week 4 | 1.2 | 2.6 |
| Prior Null Response, Week 8 | 3.7 | 5.3 |
| Prior Null Response, Week 12 | 6.1 | 5.3 |
| Prior Partial Response, Week 2 | 0 | 0 |
| Prior Partial Response, Week 4 | 2.4 | 0 |
| Prior Partial Response, Week 8 | 2.4 | 0 |
| Prior Partial Response, Week 12 | 2.4 | 0 |
| Prior Relapse, Week 2 | 0 | 0 |
| Prior Relapse, Week 4 | 0 | 0 |
| Prior Relapse, Week 8 | 0 | 0 |
| Prior Relapse, Week 12 | 1.2 | 0 |
| Total, Week 2 | 0 | 0 |
| Total, Week 4 | 3.7 | 2.6 |
| Total, Week 8 | 3.7 | 5.3 |
| Total, Week 12 | 9.8 | 5.3 |
On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Futility rules: 1) Virologic breakthrough (at least 1 log10 increase from nadir or confirmed detectable HCV RNA after undetectable HCV RNA) from Day 1 through Week 24 or 48 (depending on treatment duration); 2) HCV RNA \>1000 IU/mL during Weeks 4 to 12, inclusive; 3) Detectable HCV RNA after Week 12. Percentages are calculated by using total number in FA set as denominator, in each category.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| Prior Null Response, Week 2 | 0 | 0 |
| Prior Null Response, Week 4 | 4.9 | 2.6 |
| Prior Null Response, Week 8 | 8.5 | 7.9 |
| Prior Null Response, Week 12 | 12.2 | 7.9 |
| Prior Null Response, Week 16 | 19.5 | 7.9 |
| Prior Null Response, Week 24 | 23.2 | 10.5 |
| Prior Null Response, Week 28 | 23.2 | 13.2 |
| Prior Null Response, Week 36 | 25.6 | 13.2 |
| Prior Null Response, Week 40 | 28.0 | 13.2 |
| Prior Null Response, Week 48 | 29.3 | 13.2 |
| Prior Partial Response, Week 2 | 0 | 0 |
| Prior Partial Response, Week 4 | 2.4 | 0 |
| Prior Partial Response, Week 8 | 2.4 | 0 |
| Prior Partial Response, Week 12 | 4.9 | 0 |
| Prior Partial Response, Week 16 | 4.9 | 2.6 |
| Prior Partial Response, Week 24 | 6.1 | 7.9 |
| Prior Partial Response, Week 28 | 6.1 | 10.5 |
| Prior Partial Response, Week 36 | 7.3 | 10.5 |
| Prior Partial Response, Week 40 | 7.3 | 10.5 |
| Prior Partial Response, Week 48 | 7.3 | 10.5 |
| Prior Relapse, Week 2 | 0 | 0 |
| Prior Relapse, Week 4 | 0 | 0 |
| Prior Relapse, Week 8 | 0 | 0 |
| Prior Relapse, Week 12 | 1.2 | 0 |
| Prior Relapse, Week 16 | 1.2 | 0 |
| Prior Relapse, Week 24 | 1.2 | 2.6 |
| Prior Relapse, Week 28 | 1.2 | 2.6 |
| Prior Relapse, Week 36 | 1.2 | 2.6 |
| Prior Relapse, Week 40 | 1.2 | 5.3 |
| Prior Relapse, Week 48 | 1.2 | 5.3 |
| Total, Week 2 | 0 | 0 |
| Total, Week 4 | 7.3 | 2.6 |
| Total, Week 8 | 11.0 | 7.9 |
| Total, Week 12 | 18.3 | 7.9 |
| Total, Week 16 | 25.6 | 10.5 |
| Total, Week 24 | 30.5 | 21.1 |
| Total, Week 28 | 30.5 | 26.3 |
| Total, Week 36 | 34.1 | 26.3 |
| Total, Week 40 | 36.6 | 28.9 |
| Total, Week 48 | 37.8 | 28.9 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes SAE as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
| percentage of participants | Group A - Black | Group B - Non-Black |
|---|---|---|
| AE | 96.3 | 100.0 |
| SAE | 8.5 | 15.8 |
Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by race and by prior response.
| participants | All Participants |
|---|---|
| Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region | 47 |
No measurements were reported for this outcome.
Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A - Black | — | 7/82 (8.5%) | 79/82 (96.3%) |
| Group B - Non-Black | — | 6/38 (15.8%) | 38/38 (100%) |
| Event | Group A - Black | Group B - Non-Black |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/82 | 2/38 |
| PancreatitisGastrointestinal disorders | 0/82 | 1/38 |
| DehydrationMetabolism and nutrition disorders | 1/82 | 1/38 |
| HypotensionVascular disorders | 0/82 | 1/38 |
| Angina pectorisCardiac disorders | 0/82 | 1/38 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/82 | 1/38 |
| Hand fractureInjury, poisoning and procedural complications | 0/82 | 1/38 |
| LacerationInjury, poisoning and procedural complications | 0/82 | 1/38 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 1/38 |
| InsomniaPsychiatric disorders | 0/82 | 1/38 |
| Event | Group A - Black | Group B - Non-Black |
|---|---|---|
| FatigueGeneral disorders | 31/82 | 26/38 |
| AnaemiaBlood and lymphatic system disorders | 40/82 | 19/38 |
| NauseaGastrointestinal disorders | 20/82 | 17/38 |
| PruritusSkin and subcutaneous tissue disorders | 33/82 | 16/38 |
| RashSkin and subcutaneous tissue disorders | 15/82 | 13/38 |
| HeadacheNervous system disorders | 14/82 | 13/38 |
| InsomniaPsychiatric disorders | 8/82 | 10/38 |
| DizzinessNervous system disorders | 7/82 | 8/38 |
| Anal pruritusGastrointestinal disorders | 16/82 | 5/38 |
| Influenza like illnessGeneral disorders | 15/82 | 7/38 |
Full Analysis (FA) Set included all enrolled participants who received at least 1 dose of any study drug.
| Age, Continuous(years) | Group A - Black | Group B - Non-Black | Total |
|---|---|---|---|
| Mean | 57.7 ± 5.59 | 55.8 ± 5.95 | 57.1 ± 5.76 |
| Sex: Female, Male(Participants) | Group A - Black | Group B - Non-Black | Total |
|---|---|---|---|
| Female | 34 | 6 | 40 |
| Male | 48 | 32 | 80 |
The record gives a start of Jan 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a
Vertex Pharmaceuticals Incorporated →